Rigel Pharmaceuticals earnings were $37.2M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest RIGL earnings report on Mar 31, 2025 announced Q1 2025 earnings of $11.4M, down 20.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RIGL reported annual earnings of $17.5M, with -169.7% growth.
Rigel Pharmaceuticals Earnings Reports & History FAQ
What were Rigel Pharmaceuticals's earnings last quarter?
On RIGL's earnings call on Invalid Date, Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q1 2025 earnings per share (EPS) of $0.64, up 236.17% year over year. Total RIGL earnings for the quarter were $11.45 million. In the same quarter last year, Rigel Pharmaceuticals's earnings per share (EPS) was -$0.47.
Is Rigel Pharmaceuticals profitable or losing money?
As of the last Rigel Pharmaceuticals earnings report, Rigel Pharmaceuticals is currently profitable. Rigel Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $37.18 million, a 287.75% decrease year over year.
What was RIGL's earnings growth in the past year?
As of Rigel Pharmaceuticals's earnings date in Invalid Date, Rigel Pharmaceuticals's earnings has grown year over year. RIGL earnings in the past year totalled $37.18 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.